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Abstract
Heart failure (HF) with atrial fibrillation (AF) is correlated with worse prognosis requiring special approach. 
Rate control has been the first line of treatment in cases of HF and AF. On the other hand, rhythm control 
has been proven to be effective in returning sinus rhythm resulting in better prognosis for patients with HF 
but not HF. Its role in cocurring cases of HF and AF is not fully understood. Thus, this study aims to analyse 
whether pharmacologic rhythm control can be applied to cases of HF and AF to reduce mortality. A search 
was conducted via PubMed, Medline, ProQuest, and Cochrane Database on January 2016. One study was 
selected after filtering process by inclusion and exclusion criteria and critical appraisal was performed. It was 
found that there was rhythm control and rate control do no have favouring effect towards  mortality shown by 
RR 1.03 (95% CI 0.90-1.17, p=0.69). Rate control has protective effect towards hospitalizations by RR of 0.92 
(95% CI 0.86 – 0.98, p=0.008, NNT=19). To conclude, rhythm control is not superior to rate control in reducing 
mortality and rate control should be still be considered as first line treatment of HF and AF.   
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Farmakologis Rhythm Control Dibandingkan dengan Rate Control pada 
Kasus Gagal Jantung dan Atrial Fibrilasi
Abstrak
Gagal jantung dengan atrial fibrilasi berhubungan dengan prognosis yang lebih buruk dan membutuhkan 
penanganan khusus. Saat ini strategi rate control merupakan terapi lini pertama pada kasus gagal jantung 
dan atrial fibrilasi. Rhythm control memberikan prognosis yang lebih baik pada pasien gagal jantung dengan 
mengembalikan sinus ritme. Kegunaan rhythm control pada kasus gagal jantung dan atrial fibrilasi sampai 
saat ini belum sepenuhnya dimengerti. Tujuan studi ini adalah menelaah apakah terapi farmakologis rhythm 
control dapat menurunkan mortalitas gagal jantung dan atrial fibrilasi. Pencarian data dilakukan di PubMed, 
Medline, ProQuest, dan Cochrane Database pada Januari 2016. Setelah penyaringan dengan kriteria inklusi 
dan eksklusi, didapatkan satu studi dan dilakukan telaah kritis terhadap studi tersebut. Didapatkan hasil 
bahwa rhythm control tidak menurunkan mortalitas dibandingkan rate control  dengan  RR 1,03 (95% CI 0,90-
1,17 p=0,69). Rate control dapat menurunkan kejadian rawat inap dengan RR of 0,92 (95% CI 0,86 – 0,98, 
p=0,008, NNT=19). Disimpulkan bahwa rhythm control tidak superior dibandingkan dengan rate control dalam 
menurunkan mortalitas dan rate control sebaiknya tetap digunakan sebagai lini pertama penanganan gagal 
jantung dan atrial fibrilasi.
Kata kunci: gagal jantung; atrial fibrilasi; pharmacologic rhythm control; rate control; atrial fibrialisi
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Introduction
As number of HF cases is increasing it is 
highly important to be able to treat this condition 
comprehensively. Statistics from American Heart 
Association mentioned that in the US one in nine 
people died due to HF showing the magnitude of 
the problem.1  Every year in the US it is the main 
cause of hospital visits and hospitalizations thus 
causing huge social and economic burden.2 It is 
estimated that every year $33 billion was spent 
on HF cases.3 AF is the most commonly found 
arrhythmia in clinical settings and estimated to be 
doubled in number by 2050.4 Framingham Heart 
Study showed that 26% participants enrolled in the 
study between 1948 to 1995 had both AF and HF.5 
It is one of the comorbidities often found along with 
HF and is associated to worse outcome.6 A study 
also showed that as the severity of HF is increasing, 
so is the number of AF found. In patients with mild 
HF, 5% was proven to have AF while in moderate 
HF 10% to 26% of these patients had AF while in 
severe HF, 50% of the patients suffered from AF.7
Currently there are options in treating AF. Rhythm 
control is used to restore the sinus rhythm while rate 
control is used to reduce ventricular response rate. 
Guideline of management in the cases of HF and 
AF recommend the use of rate control using agents 
such as beta blockers, digoxin, or calcium channel 
blockers.8 However, in cases of AF alone, especially 
when symptomatic, the use of rhythm control is more 
preferred compared to rate control.8 
It is essential to understand the advantages 
and disadvantages of a treatment before giving it 
to the patients. As the number of cases with HF 
and AF is ever increasing, we would like to find 
out whether treatment with pharmacologic rhythm 
control can reduce mortality rate in HF patients with 
AF in comparison with rate control.
Case Illustration
A 46 year old female patient came with the chief 
complaint of shortness of breath worsening since 
three days before admission. Shortness of breath 
occurred during mild exertion such as walking for 
five meters and relieved at rest. Shortness of breath 
often kept patient awake during the night and she 
had to use three pillows.  Patient’s legs were also 
swollen since the past 3 days. Before the onset of 
shortness of breath, patient recalled having chest 
pain occurred on the left side and radiating to the 
right side up until her back.  Pain accompanied by 
cold sweat and present. Previously patient had been 
diagnosed with heart failure (HF) for 1 year and was 
also diagnosed with valvular heart disease since 7 
years earlier. Patient had no history of hypertension 
and diabetes mellitus. From physical examination, 
it was found that patient had tachypnea with the 
respiratory rate of 26 times per minute, tachycardia 
with heart rate of 110 times per minute, enlarged 
heart borders, systolic murmur at the apex with 
the grade of 3/6 and mid-diastolic murmur with the 
grade of 4/6 at the tricuspid valve, rales at the base 
of the lungs, and edema on both legs. From ECG, it 
was found that patient had atrial fibrillation (AF) with 
heart rate of 110x per minute. From chest x– ray, 
patient had cardiothoracic ratio (CTR) of 70%. 
Clinical Question
Is pharmacologic rhythm control more effective 
in reducing mortality compared to rate control in 
patients with HF and AF? 
Methods
A comprehensive search via Pubmed®, 
Proquest®, Medline®, and Cochrane® databases 
were conducted using search term “HF AND AF 
AND pharmacologic rhythm control AND rate control 
AND mortality” on January 31st, 2016.  Results 
were narrowed based upon inclusion criterias, such 
as clinical study, clinical trial, journal article, meta-
analysis, and systematic reviews, within 10 years 
of publication, and studies conducted on human. 
Afterwards, screening of titles and abstracts were 
performed to exclude studies which are not suitable for 
our clinical questions which were invasive procedures. 
Full text analysis were done to analyse which studies 
could be used for our purpose. Flowchart of each 
database search is as presented in Figure 1. 
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The studies were then appraised using 
appraisal tools from the Center of Evidence-
Based Medicine, University of Oxford for therapy 
and meta – analysis studies.9
Results
This study focuses on the effectiveness of 
rhythm control in reducing mortality compared to 
rate control in patients with HF and AF. The primary 
endpoint of the study was all-cause mortality.
Figure 1. Flowchart of Search Process Conducted on January 31st, 2016
After a thorough searching method through few 
databases of Pubmed®, Cochrane®, ProQuest®, 
and Medline®, two studies were found to be in 
theme with the clinical question. These studies 
were Caldera, et al. 10 and Chatterjee, et al.11 
However, after further reading, study by Chatterjee, 
et al. was excluded because the studies involved in 
the meta-analysis involved patients with AF alone 
without presence of HF. The study by Caldeira, et 
al.10 was reviewed for its validity and relevance as 
shown in Table 1 and is summarized in Table 2. 
Search via Pubmed®, Medline®,
Cochrane Database®, Proquest®,
Keyword: heart failure AND atrial
fibrillation AND pharmacologic
rhythm control AND rate control AND
mortality
114 studies found
7 studies found
2 studies found
Full Text Assessment
Screening of tiles and 
abstracts
Filters:
Articles in English
Systematic reviews,
Meta-analysis, Clinical
study,Clinical trial,
Journal article, Full Text 
Published within 10 years
Studies in Human
1 study
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The study by Caldeira et al10  was a meta-
analysis published in 2011 and involved 4 
randomised controlled trials (RCT) with the total of 
2486 patients with HF and AF. The study compared 
pharmacological rhythm control and rate control 
in such patients. The authors then searched for 
studies relevant to their studies via CENTRAL and 
MEDLINE databases using proper search terms.10 
Inclusion criteria included RCT, pharmacological 
management of rhythm and rate control, HF 
patients with minimum New York Heart Association 
(NYHA) class of 2 or ejection fraction of less than 
50%. Any studies with invasive methods of rhythm 
control including catheter ablation technique were 
not included to the analysis.10 
The studies found were then assessed for 
PEDro score for its quality which all scored 6 to 7 out 
of 11 points showing fair qualities of the studies.12 
The score featured eligibility criteria, random 
allocation, allocation, concealment, similar baseline 
characteristics, blinding of subjects, blinding 
of therapists, blinding of outcome assessors, 
crossover rate of less than 15%, intention-to-treat 
analysis, statistical comparisons between groups, 
and measures of variability. Studies were then 
analysed using revman version 5.0.23 in which 
relative risk (RR) was found. Results were written 
in 95% confidence intervals (CI) and assessed for 
its heterogeneity using I2 test which revealed that 
the studies used were homogenous by I2 of 0%.10 
The primary endpoint of the study was mortality 
while other complications such as hospitalisations, 
stroke or thromboembolic complications were 
also assessed. For mortality, RR did not differ 
significantly between two treatments as it was 
1.03 (95% CI 0.90-1.17, p=0.69).10  There are four 
studies included in the analysis and they showed 
mostly consistent results.10 
For hospitalization, the result was supportive 
towards rate control with RR of 0.92 (95% CI 0.86 
– 0.98, p=0.008).10 For clinical importance, number 
needed to treat (NNT) calculation was performed 
and it was found that NNT was 19. For stroke or 
thromboembolic complications, RR was 1.09 (95% 
CI 0.61 – 1.96, p=0.77).10
The study showed importance of the 
pharmacologic rhythm control and rate control in 
managing HF and AF. These results can be applied 
in the patient with both HF and AF. This would be 
beneficial in determining treatment for our patient 
as treatment may help reducing hospitalisation but 
not mortality. 
Table 2. Summary of Study Used All-Cause Mortality as the Endpoint10
Results Summary
Pharmacologic rhythm control does not reduce mortality rate when 
compared to rate control RR 1.03 (95% CI 0.90-1.17, p=0.69)
Rate control strategy reduces hospitalizations in 
patients with HF and AF. Neither strategy showed 
favouring effects towards mortality and stroke or 
thromboembolic complications.
Hospitalization is reduced in rate control patients compared to 
patients with pharmacologic rhythm control RR 0.92 (95% CI 0.86-
0.98, p=0.008, NNT=19) 
There is no reduction in stroke or thromboembolic complications 
RR 1.09 (95% CI 0.61-1.96, p=0.77).
Table 1. Validity and Relevance Assessment of The Study Included10
Validity
Year PICO Appropriate Searching
Relevant 
Study 
Included
Quality 
Assessment 
ofTrials
Heterogeneity Level of Evidence
2011 + + + + + 1
+ present in the study
- not present in the study
? not stated in the study
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Discussion
In cases of HF, there are few hypotheses on 
how AF develops. One of the pathophysiological 
pathways is from the neurohormonal imbalance 
and activation of the renin-angiotensin-aldosterone 
system (RAAS).13 This results in left atrial stretch 
and fibrosis thus the impairment of conduction.6 
Impaired calcium handling and calcium overload in 
HF also contributes to the development of AF.13
Current guideline published by American 
Heart Association supports the use of rate control 
agents in cases of HF and atrial HF. Rate control 
preferred in these cases are beta blockers or non 
dihydropyridine calcium channel blocker which 
can be used in conjunction with digoxin.8 Previous 
studies have shown that beta blockers could reduce 
mortality, hospitalization, and cardiovascular (CV) 
death when compared with the use of placebo. A 
meta – analysis showed that when compared to 
placebo, beta blockers could reduce the all – cause 
mortality to 0.73 (95% CI 0.67 – 0.80) in cases 
of sinus rhythm.14 While in presence of AF, beta 
blockers could reduce the risk ratio was 0.97 (95% 
CI 0.83 – 1.14).14 Beta blockers are used due to their 
high sympathetic and negative inotropic effects. 
Other preferred agent of rate control is digoxin which 
belongs to the class of cardiac glycosides. Currently, 
the prescription of digoxin has not been proven to 
reduce mortality, especially as digoxin itself has risk 
of toxicity. A study by the af follow-up investigation 
of rhythm management (AFFIRM) study found 
an association of increased mortality with the use 
of digoxin with or without presence of HF.15 Non – 
dihydropridine calcium channel blockers are also an 
option because their negative inotropic effects and 
reduction of risk of re-infarction and cardiac death to 
1.41 (95% CI 1.01-1.96).16
Approaches to control heart rate should 
mind the optimal heart rate of these patients. A 
study conducted in 33 centers in the Netherlands 
followed up patients for 12 months, lenient rate 
control, in which the goal of resting  heart rate was 
below 110, was proven to have hazard ratio of 
0.79 (90% CI 0.38 – 1.65) in comparison to strict 
rate control, which had goal of resting heart rate of 
below 80 beats per minute.17 Difference of mortality 
in groups attributed to lenient rate control and strict 
rate control was significant (p<0.0001).17 Thus it 
may be wiser to be less aggressive in reducing the 
heart rate in patients with HF and AF. 
Rhythm control, on the other hand, aims on the 
reversing to sinus rhythm. This could be achieved via: 
cardioversion, antiarrhythmic drugs, and catheter 
ablation. Cardioversion should be used in cases 
where haemodynamic disturbances are found. 
Antiarrhymtic drugs approved for the usage in HF 
and AF are only dofetilide and amiodarone.13 These 
drugs should also be used in caution as they are 
toxic. Amiodarone has been proven to be effective 
in preventing the recurrence of AF with odds ratio of 
0.15 (95% 0.10 – 0.22) and had better results when 
compared to sotalol (OR 0.47, 95% CI 0.36 – 0.69) 
and dronedarone (OR 0.42, 95% CI 0.29 – 0.60).18 
The question remains whether reversing to 
sinus rhythm is essential in reducing mortality of 
patients with both HF and AF. It has been widely 
studied that presence of HF with concurring AF 
yields poorer prognosis and HF with sinus rhythm 
has better outcome especially in terms of mortality, 
hospitalizations, and other complications. In 
patients with HF and AF, a study showed that when 
the rhythm has returned to sinus, the patients had 
significant improvement of left ventricular ejection 
fraction with the mean difference of 11.1% (95% CI 
7.1 – 15.2, p<0.001).19
According to Canadian Cardiovascular Society, 
there are few indicators in determining the proper 
management in cases of AF and HF. For those 
with: persistent AF, less symptoms, age above 65 
years old, hypertension, no history of HF, previous 
failure of antiarrhythmic drugs, rate control is more 
favorable. On the other hand, those with paroxysmal 
AF or newly detected AF, symptomatic patients, 
age below 65 years old, no history of hypertension, 
exacerbation of HF by AF, no history of failure when 
treated by antiarrhythmic drugs, have more benefits 
when treated with rhythm control. However, patient 
preferences should always be taken into account 
when determining which treatment is used. 
The result of the study we found stated that 
there was no difference of mortality in patients 
treated with rhythm control when compared to 
rate control (RR 1.03 95%CI 0.90 – 1.17, p=0.69). 
However, it was found that hospitalization rate was 
significantly lower in group of rate control with the 
NNT of 19 (p=0.008).  This result is in conjunction 
with another meta-analysis studying the outcome 
of beta blockers use in patients with HF and AF 
showing that there is also no reduction of mortality in 
patients with AF and HF treated with beta  blockers. 
However, the reduction of hospitalization was not 
seen in patients in this study. The heterogeneity of 
sample population is also shown in I2 which was 0% 
indicating that the heterogeneity of the population 
was minimal. However, there was no information 
regarding baseline characteristics of the patients 
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sampled in the study. This could be a suggestion 
to improve the quality of study by Caldeira et 
al10 as baseline characteristics may play role in 
determining the prognosis of the patient. Women 
had higher mortality in comparison to men with 
both HF and AF (HR 2.7, 95% CI 2.0 – 3.6 vs HR 
1.6, 95% CI 1.2 – 2.1).5 Presence of other risk 
factors such as coronary heart disease, chronic 
kidney disease, and the functional class of the HF 
also determine prognosis of HF.20
A review done by Kotecha and Piccini in 2015 
summarized priorities in treatment of HF and AF.13 In 
patients with HF, the top 3 priorities are euvolemia, 
diminish RAAS disturbances, and managing non 
– cardiovascular comorbidity.13 While in patients 
with AF, preventing complications such as stroke 
and embolism, controlling rapid heart rate, and 
managing non – cardiovascular comorbidity are 
the priorities.13 In patients with AF and HF, restoring 
sinus rhythm via pharmacologic management is not 
the priority.13 There has been few hypotheses on 
why pharmacological rhythm control is superior in 
reducing mortality in patients with AF only but not 
in patients with HF and AF.13 Limited efficacy, side 
effects, irreversibility of damage caused by AF, and 
difficulties of maintaining the rhythm name a few of 
the hypotheses.13 In patients undergo rhythm control 
in AF and congestive HF (AF-CHF) trial, 58% of these 
patients had at least one episode of AF during follow 
up period proving that achieving and maintaining 
sinus rhythm may be a challenge needed.21 
This should be our consideration in determining 
therapeutic goals of our patients. The use of rate 
control would not reduce mortality in patients with 
HF and AF. However, it may be beneficial in reducing 
hospitalization eventhough there is still inconsistent 
results. Returning to sinus rhythm has not been 
proven to be effective in reducing mortality and there 
is also risk of returning to AF. There is also no proof 
that it would be beneficial in reducing hospitalizations 
but there is still evidence of reduction in symptoms 
of HF. Weighing risk and benefit ratio the use of rate 
control with the first choice of beta blockers can be 
current option in management of AF and HF. The 
use of rhythm control should be considered when 
rate control fails to ameliorate symptoms of AF in 
these population of patients. 
Conclusion
Pharmacologic rhythm control does not reduce 
mortality of patient with HF and AF when compared 
to rate control. Patients given rate control are 
proven to have less hospitalization when compared 
to patients given rhythm control (p=0.008). A critical 
appraisal has been done to study done by Caldeira 
et al10 and it has been concluded that the study 
was valid, important, and applicable to cases met 
in daily clinical practice. 
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